Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 5/20 | 0.70 |
| ▸ | NADK | O95544 | 1/20 | 0.66 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.64 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.57 |
| ▸ | AMD1 | P17707 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097372 | 1.00 | GAPDH (0.80) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1097445 | 0.89 | GAPDH (1.00) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1097451 | 0.89 | GAPDH (1.00) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1106676 | 0.89 | GAPDH (1.00) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL15906322 | 0.89 | GAPDH (1.00) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1099264 | 0.88 | GAPDH (0.83) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1099269 | 0.88 | GAPDH (0.83) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL13127239 | 0.83 | SLC28A2 (1.00) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL1099005 | 0.82 | GAPDH (0.76) | GAPDHHSD17B10SLC28A2NADKHSPA8 | |
| SCHEMBL1098999 | 0.82 | GAPDH (0.76) | GAPDHHSD17B10SLC28A2NADKHSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765844-B1 | PURINE NUCLEOTIDE DERIVATIVES | SOLVELL AS (NO) | 2014-07-30 | — | — | EP | disclosed |
| US-8153609-B2 | Purine nucleotide derivatives | LAURAS AS (NO) | 2012-04-10 | — | — | US | disclosed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | disclosed |
| CN-101001865-A | Purine nucleotide derivatives | LAURAS AS (NO) | 2007-07-18 | — | — | CN | disclosed |
| EP-1765844-A2 | PURINE NUCLEOTIDE DERIVATIVES | Lauras AS (NO) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123755-A2 | PURINE NUCLEOTIDE DERIVATIVES | LAURAS AS (NO) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | GAPDH 1967/4885HSD17B10 4521/4885SLC28A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.